Search Results 91-100 of 16732 for CLL

1. A Study to Compare ACP-196 and Obinutuzumab with Chlorambucil, or ACP-19 alone, with Obinutuzumab and Chlorambucil, for Patients with Previously Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

   ... chronic lymphocytic leukemia (CLL). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

2. A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

3. Financial Difficulty in Patients With Blood Cancer - Mayo Clinic

   ... chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250), a physician survey (n=100), and a practice survey completed by each site ...

4. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with ...

5. Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or ...

6. Study of Hodgkin Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Lymphoma Epidemiology Laboratory - Mayo Clinic Research

   Dr. Cerhan's NHL & CLL case-control study at Mayo Clinic tests hypotheses about the etiology of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

7. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT) - Mayo Clinic

   A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT). Print details. Share; Facebook ...

8. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions - Mayo Clinic

   ... chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors. Participation eligibility. Participant eligibility includes age ...

9. Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

   Patients must be diagnosed with CLL in accordance with International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria that includes all of the ...

10. A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

    ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participation eligibility. Participant eligibility includes age, gender, type and ...